Expertise in
31
conditions

Dr. Michael Naughton

Hematology
Office
211 Saint Francis Dr Ste 372, 
Cape Girardeau, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
31
conditions
Office
211 Saint Francis Dr Ste 372, 
Cape Girardeau, MO 

Overview

Michael Naughton is a Hematologist in Cape Girardeau, Missouri. Dr. Naughton is highly rated in 31 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

His clinical research consists of co-authoring 64 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in MO

Hospital Affiliations

Barnes-Jewish St Peters Hospital
Saint Francis Medical Center
Mercy Hospital Southeast

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Office
211 Saint Francis Dr Ste 372, Cape Girardeau, MO 63703

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Enrollment Status: Recruiting
Publish Date: July 28, 2025
Intervention Type: Drug, Behavioral, Other
Study Drugs: Goserelin, Anastrozole, Exemestane, Fulvestrant, Tamoxifen
Study Phase: Phase 2
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: August 20, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
Enrollment Status: Terminated
Publish Date: November 07, 2022
Intervention Type: Drug, Procedure
Study Drugs: Docetaxel, Carboplatin
Study Phase: Phase 2
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
Enrollment Status: Terminated
Publish Date: November 01, 2022
Intervention Type: Drug, Biological
Study Drugs: Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil
Study Phase: Phase 2
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Procedure, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

64 Total Publications

Transmission anomalies in 2D photonic crystals from the checkerboard family: from broken to hidden symmetries and plasmon "spoofing".
Transmission anomalies in 2D photonic crystals from the checkerboard family: from broken to hidden symmetries and plasmon "spoofing".
Journal: Optics express
Published: June 14, 2025
Similar Doctors
Expertise in
59
conditions
Dr. Andrew Dickey
Hematology
Expertise in
59
conditions
Dr. Andrew Dickey
Hematology

Mercy Cancer Center-Cape Girardeau

789 S Mount Auburn Rd, 
Cape Girardeau, MO 
 (1.5 miles away)
573-519-4830
Languages Spoken:
English
See accepted insurances

Andrew Dickey is a Hematologist in Cape Girardeau, Missouri. Dr. Dickey is highly rated in 59 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Penile Cancer, and WT1-Related Wilms Tumor Syndromes.

Expertise in
44
conditions
Dr. Muhammad Popalzai
Hematology
Expertise in
44
conditions
Dr. Muhammad Popalzai
Hematology

SIH Cancer Institute

1400 Pin Oak Dr, 
Carterville, IL 
 (39.7 miles away)
618-985-3333
Languages Spoken:
English
See accepted insurances

Muhammad Popalzai is a Hematologist in Carterville, Illinois. Dr. Popalzai is highly rated in 44 conditions, according to our data. His top areas of expertise are Gallbladder Adenocarcinoma, Large-Cell Immunoblastic Lymphoma, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

Expertise in
82
conditions
Dr. Winston Chua
Hematology | Oncology
Expertise in
82
conditions
Dr. Winston Chua
Hematology | Oncology

Oncology Associates Inc PSC

2603 Kentucky Ave Ste 403, 
Paducah, KY 
 (58.5 miles away)
618-252-1815
Languages Spoken:
English
See accepted insurances

Winston Chua is a Hematologist and an Oncologist in Paducah, Kentucky. Dr. Chua is highly rated in 82 conditions, according to our data. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Lung Cancer, and Pleuropulmonary Blastoma.

Frequently Asked Questions about Dr. Michael Naughton

How do I make an appointment with Dr. Michael Naughton?

You can book an appointment with Dr. Michael Naughton by calling their office at 573-331-5525. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael Naughton a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael Naughton is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael Naughton specialize in?

While Dr. Michael Naughton is a Hematology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Michael Naughton participate in research or clinical trials?

Yes. Dr. Michael Naughton has published 64 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Michael Naughton's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael Naughton accept my insurance?

Dr. Michael Naughton accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 573-331-5525 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Naughton's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 18 Advanced Conditions
View All 76 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile